What to expect from Pfizer's (PFE) Q3 earnings

What happened

Pfizer is scheduled to report its third-quarter results on Tuesday before the market opens. Last quarter, it reported revenue of $15.03 billion, up 2.6% year on year, and beat analysts’ revenue and earnings-per-share estimates, but missed their full-year earnings-per-share guidance estimates.

Confirmed

Global impact / market context

The report will show whether Pfizer’s revenue is tracking the expected year-on-year decline of 4.8%. Revenue below expectations could weigh on investor views of sales momentum, while stronger results could support confidence; earnings and guidance may also shape expectations for future profits.

Analyst inference

Analysts have generally reconfirmed their estimates over the past 30 days, indicating expectations have not shifted much. Results from peers offer mixed context: Eli Lilly and Supernus both beat revenue expectations and posted growth, but their performance does not establish Pfizer’s outcome.

Analyst inference

What to watch

1. Pfizer’s reported third-quarter revenue versus the expected 4.8% year-on-year decline; the gap would indicate whether sales are performing better or worse than analysts anticipate. Analyst inference
2. Earnings per share, meaning profit allocated to each share, and any full-year guidance; last quarter Pfizer beat earnings estimates but missed full-year earnings guidance estimates. Analyst inference
3. Whether Pfizer’s results prompt analysts to revise their estimates, which could change investor expectations for future sales and profits after estimates were generally reconfirmed in the past 30 days. Analyst inference

Evidence

• stockstory.org